Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | PI103 | 1 | 72 | 1.0 | 2166.0 | 5476.0 | 1443.3 | 0.0 | 0.235 | 0.396 | 1.924 | BT20 PI103 0 1 |
| BT-20 | AS605240 | 1 | 72 | 1.0 | 5369.8 | 6371.0 | 1443.3 | 0.0 | 0.847 | 0.843 | 2.142 | BT20 AS605240 0 1 |
| BT-20 | Omipalisib | 1 | 72 | 1.0 | 262.3 | 6095.3 | 1443.3 | 0.0 | -0.560 | 0.043 | 2.078 | BT20 GSK458 0 1 |
| BT-20 | AZD-6482 | 1 | 72 | 1.0 | 3655.0 | 5948.8 | 1443.3 | 0.0 | 0.576 | 0.614 | 2.043 | BT20 AZD6482 0 1 |
| BT-20 | Dactolisib | 1 | 72 | 1.0 | 1253.8 | 5998.3 | 1443.3 | 0.0 | -0.066 | 0.209 | 2.055 | BT20 BEZ235 0 1 |
| BT-20 | MK2206 | 1 | 72 | 1.0 | 4545.8 | 6138.5 | 1443.3 | 0.0 | 0.732 | 0.741 | 2.089 | BT20 MK2206 0 1 |
| BT-20 | WYE-125132 | 1 | 72 | 1.0 | 2450.3 | 5739.3 | 1443.3 | 0.0 | 0.304 | 0.427 | 1.991 | BT20 WYE125132 0 1 |
| BT-20 | Sirolimus | 1 | 72 | 1.0 | 3619.3 | 5856.5 | 1443.3 | 0.0 | 0.576 | 0.618 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | AZD-6482 | 2 | 72 | 1.0 | 1651.0 | 3186.5 | 1018.6 | 0.0 | 0.341 | 0.518 | 1.645 | BT20 AZD6482 0 2 |
| BT-20 | TGX221 | 1 | 72 | 1.0 | 5819.3 | 5723.8 | 1443.3 | 0.0 | 1.020 | 1.020 | 1.988 | BT20 TGX221 0 1 |
| BT-20 | Torin1 | 1 | 72 | 1.0 | 1708.3 | 5863.3 | 1443.3 | 0.0 | 0.087 | 0.291 | 2.022 | BT20 Torin1 0 1 |
| BT-20 | BX-912 | 2 | 72 | 1.0 | 2918.0 | 3312.0 | 1018.6 | 0.0 | 0.857 | 0.881 | 1.701 | BT20 BX912 0 2 |
| BT-20 | Buparlisib | 1 | 72 | 1.0 | 2154.3 | 6321.8 | 1443.3 | 0.0 | 0.207 | 0.341 | 2.131 | BT20 BKM120 0 1 |
| BT-20 | KIN001-244 | 1 | 72 | 1.0 | 5975.3 | 6295.0 | 1443.3 | 0.0 | 0.952 | 0.949 | 2.125 | BT20 KIN001-244 0 1 |
| BT-20 | GDC-0980 | 1 | 72 | 1.0 | 1191.0 | 5778.5 | 1443.3 | 0.0 | -0.092 | 0.206 | 2.001 | BT20 GDC0980 0 1 |
| BT-20 | Everolimus | 1 | 72 | 1.0 | 3532.8 | 5781.0 | 1443.3 | 0.0 | 0.564 | 0.611 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Alpelisib | 1 | 72 | 1.0 | 3559.0 | 6091.5 | 1443.3 | 0.0 | 0.544 | 0.584 | 2.077 | BT20 BYL719 0 1 |
| BT-20 | Trametinib | 1 | 72 | 1.0 | 3683.0 | 5837.3 | 1443.3 | 0.0 | 0.592 | 0.631 | 2.016 | BT20 Trametinib 0 1 |
| BT-20 | Omipalisib | 2 | 72 | 1.0 | 235.0 | 3349.0 | 1018.6 | 0.0 | -0.574 | 0.070 | 1.717 | BT20 GSK458 0 2 |
| BT-20 | AZD8055 | 1 | 72 | 1.0 | 2287.8 | 5941.5 | 1443.3 | 0.0 | 0.253 | 0.385 | 2.041 | BT20 AZD8055 0 1 |
| BT-20 | BX-912 | 1 | 72 | 1.0 | 5764.8 | 6155.0 | 1443.3 | 0.0 | 0.938 | 0.937 | 2.092 | BT20 BX912 0 1 |
| BT-20 | Pictilisib | 1 | 72 | 1.0 | 3772.0 | 6125.0 | 1443.3 | 0.0 | 0.585 | 0.616 | 2.085 | BT20 GDC0941 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 1.0 | 5741.0 | 6240.0 | 1443.3 | 0.0 | 0.923 | 0.920 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | AZD-6482 | 3 | 72 | 1.0 | 2162.8 | 3560.8 | 586.9 | 0.0 | 0.651 | 0.607 | 2.601 | BT20 AZD6482 0 3 |
| BT-20 | AS605240 | 3 | 72 | 1.0 | 2935.8 | 3575.0 | 586.9 | 0.0 | 0.854 | 0.821 | 2.607 | BT20 AS605240 0 3 |